NIIMBL announced it is partnering with FDA through the University of Delaware to improve biopharmaceutical manufacturing.
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that the University of Delaware entered into a Collaborative Research and Development Agreement (CRADA) with FDA on July 15, 2019, according to a July 31, 2019 press statement.
Through the CRADA, FDA and NIIMBL will have the ability to support investments in regulatory science research and training needed to promote advanced manufacturing innovations in areas such as continuous manufacturing, on-demand manufacturing, and advanced process control technologies.
“Biopharmaceuticals are more challenging to manufacture than traditional pharmaceuticals, and NIIMBL seeks to enhance patient access by innovating the biopharmaceutical manufacturing technologies and processes,” said Kelvin Lee, NIIMBL institute director, in the press statement. “This CRADA establishes a framework for FDA engagement in NIIMBL projects and initiatives that strengthens the existing NIIMBL-FDA relationship and supports the development of advanced biopharmaceutical manufacturing innovations.”
Source: NIIMBL
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.